EcoDrugPlus

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSONIG00000012530
Gene Symbol: UGCG
4 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSONIG00000015520
Gene Symbol: WEE1
4 Cross references
205 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSONIG00000006089
Gene Symbol: YES1
4 Cross references
208 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSONIG00000003842
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSONIG00000018510
Gene Symbol: ACVR2B
4 Cross references
195 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSONIG00000017364
Gene Symbol: ACVR2BA
1 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSONIG00000031348
Gene Symbol: ADORA1
4 Cross references
204 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSONIG00000003826
Gene Symbol: ADORA2A
4 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSONIG00000032812
Gene Symbol: ADORA2A
3 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSONIG00000031032
Gene Symbol: ADORA2B
1 Cross references
198 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSONIG00000012836
Gene Symbol: ADORA2B
1 Cross references
198 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSONIG00000016511
Gene Symbol: ADA
4 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).